

FORMAT EUROPEAN CURRICULUM VITAE



PERSONAL INFORMATION

Name **GIANLUCA BOSSI**
Address Via Elio Chianesi 53, 00144 Rome, ITALY
Telephone +39-06-52666995
Fax +39-06-52662505
E-mail gianluca.bossi@ifp.gov.it; bossigianluca@hotmail.com
Nationality Italian

EDUCATION AND TRAINING

- Date (da – a) 01 August 2018 – 01 August 2024
National Scientific Qualification competition sector 05/E2 – Molecular Biology - II fascia
- Date (da – a) 18 September 2018 – 18 September 2024
National Scientific Qualification competition sector 05/F1 – Applied Biology - II fascia
- Date (da – a) 1997-2002
• Name and type of educational or training institution University of Rome “Sapienza”, Policlinico Umberto I
 - Main subjects / Professional skills studied Specialty in Clinical Patology
 - Qualification achieved Diploma
- Level in national classification (if appropriate) 70/70
- Date (da – a) Agosto 17-28, 1997
• Name and type of educational or training institution A Nato Advanced Study Institute on Gene Therapy, Spetsay
 - Main subjects / Professional skills studied Gene Therapy course
 - Qualification achieved Participation certificate
- Level in national classification (if appropriate)
- Date (da – a) July 1995
• Name and type of educational or training institution University of Rome “Sapienza”
 - Main subjects / Professional skills studied Biological Science
 - Qualification achieved Degree
- Level in national classification 109/110

(if appropriate)

FINANCING RECEIVED FOR RESEARCH ACTIVITIES

- Date (from – to) 2017-2020
- Name and type of education or training institution AIRC Foundation for Cancer Research, Project IG.2016 Id.18449, (88.000,00 Euro/year)
IRCCS – Regina Elena National Cancer Institute, Oncogenomic and Epigenetic Unit, Department of Diagnostic Research and Technological Innovation.
- Main subjects / professional skills studied "Investigating MKK3 as novel molecular target for therapeutic strategy in microsatellite stable colorectal cancer."
- Qualification achieved Principal Investigator

- Date (from – to) 2015-2016
- Name and type of education or training institution Umberto Veronesi Foundation
IRCCS – Regina Elena National Cancer Institute, Laboratory of Medical Physics and Expert Systems
- Main subjects / professional skills studied Molecular Biology, Cell Biology and Biochemistry to study the involvement of functional p53 in the generation of the Abscopal Effect following Radiotherapy.
- Qualification achieved Senior Fellowship

- Date (from – to) 2010-2012
- Name and type of education or training institution AIRC, Foundation for Cancer Research, Project 8804 (50000 Euro /year).
IRCCS – Regina Elena National Cancer Institute, Oncogenesis Laboratory
- Main subjects / professional skills studied Molecular Biology, Cell Biology and Biochemistry for the study of the involvement of mutated p53 proteins in the modulation of the tumor microenvironment.
- Qualification achieved Principal Investigator

- Date (from – to) 2000-2001
- Name and type of education or training institution FIRC, Italian Foundation for Cancer Research
Mc Master University, Life Science Building, department of biology, Hamilton, Canada
- Main subjects / professional skills studied Molecular Biology, Cell Biology and Biochemistry for the Development of New Adenoviral Vectors for Gene Therapy.
- Qualification achieved Post-doctoral Fellowship for Researcher Abroad

- Date (from – to) 1997-1999
- Name and type of education or training institution FIRC, Italian Foundation for Cancer Research
IRCCS – Regina Elena National Cancer Institute, Oncogenesis Laboratory
- Main subjects / professional skills studied Molecular Biology, Cell Biology, Biochemistry for wtp53 delivery in cancer gene therapy approaches.
- Qualification achieved Fellowship

WORK-PROFESSIONAL EXPERIENCE SCIENTIFIC ACTIVITY

- Date (from – to) January 2016 - May 2020
- Name and address of the employer Alliance Against Cancer (ACC), Via Giorgio Ribotta 5, 00144 Rome

- Type of business or sector
 - IRCCS – Regina Elena National Cancer Institute, via Elio Chianesi 53, 00144 Rome
- Kind of employment
 - Oncogenomic and Epigenetic Unit, Laboratory of Medical Physics and Expert Systems, Department of Diagnostic Research and Technological Innovation,
- Main duties and responsibilities
 - Senior Researcher IRE- ACC;
 - External collaborator at the Italian Ministry of Health;
 - Dissect molecular events involved in abscopal effect induced by radiotherapy;
 - Investigate MKK3 as target in anticancer therapy in colorectal cancer;
 - Identification and validation of molecular biomarkers for the development of new anticancer therapies.
- Date (from – to)
 - Jannary 2015 - December 2015
- Name and address of the employer
 - Umberto Veronesi Foundation, Piazza Velasca 5 - 20122 Milan
 - Alleanza Against Cancer (ACC), Via Giorgio Ribotta 5, 00144 Rome
 - IRCCS – Regina Elena National Cancer Institute, via Elio Chianesi 53, 00144 Rome
- Type of business or sector
 - Laboratory of Medical Physics and Expert Systems, Department of Diagnostic Research and Technological Innovation,
- Kind of employment
 - Senior Researcher Veronesi - ACC;
- Main duties and responsibilities
 - External collaborator at the Italian Ministry of Health;
 - study of the contribution of the wild type p53 protein in the abscopal effect induced by radiotherapy.
- Date (from – to)
 - May 2014 - December 2014
- Name and address of the employer
 - Alleanza Against Cancer (ACC), Via Giorgio Ribotta 5, 00144 Rome
 - IRCCS – Regina Elena National Cancer Institute, via Elio Chianesi 53, 00144 Rome.
- Type of business or sector
 - Laboratory of Medical Physics and Expert Systems, Department of Diagnostic Research and Technological Innovation,
- Kind of employment
 - Senior Researcher IRE-ACC
- Main duties and responsibilities
 - External collaborator at the Italian Ministry of Health;
 - study of the contribution of the wild type p53 protein in the abscopal effect induced by radiotherapy;
 - Study of the mutated p53 roles in modulating the tumor microenvironment.
- Date (from – to)
 - June 2013 – April 2014
- Name and address of the employer
 - IRCCS – Regina Elena National Cancer Institute, via Elio Chianesi 53, 00144 Rome.
- Type of business or sector
 - Laboratory of Medical Physics and Expert Systems, Department of Diagnostic Research and Technological Innovation,
- Kind of employment
 - Senior Researcher Collaborator
- Main duties and responsibilities
 - study of the contribution of the wild type p53 protein in the abscopal effect induced by radiotherapy;
 - Study of the mutated p53 roles in modulating the tumor microenvironment.
- Date (from – to)
 - June 2012 - June 2013
- Name and address of the employer
 - IRCCS – Regina Elena National Cancer Institute, via Elio Chianesi 53, 00144 Rome.
- Type of business or sector
 - Scientific Direction / Molecular Oncogenesis Laboratory (Dr. S. Soddu)

- Kind of employment Senior Researcher Collaborator
 - Main duties and responsibilities - Study of the mutated p53 roles in modulating the tumor microenvironment.
- Date (from – to) May 2010 - May 2012
 - Name and address of the employer IRCCS – Regina Elena National Cancer Institute, via delle Messi D'Oro, 156, 00158 Rome
 - Type of business or sector Molecular Oncogenesis Laboratory
 - Kind of employment Senior Researcher Group Leader
 - Main duties and responsibilities - Study of the mutated p53 roles in modulating the tumor microenvironment.
- Date (from – to) July 2009 - April 2010
 - Name and address of the employer IRCCS – Regina Elena National Cancer Institute, via delle Messi D'Oro, 156, 00158 Rome
 - Molecular Oncogenesis Laboratory (Dr. A. Sacchi),
 - Kind of employment Senior Researcher Collaborator
 - Main duties and responsibilities Mutant p53 as a target for improved cancer treatments.
- Date (from – to) July 2007 - June 2009
 - Name and address of the employer IRCCS – Regina Elena National Cancer Institute, via delle Messi D'Oro, 156, 00158 Rome
 - Scientific Direction / Molecular Oncogenesis Laboratory (Dr. A. Sacchi),
 - Kind of employment Senior Researcher Collaborator
 - Main duties and responsibilities RNA interference in vivo to define the role of genes mainly involved in malignancy
- Date (from – to) February 2003 - May 2007
 - Name and address of the employer IRCCS – Regina Elena National Cancer Institute, via delle Messi D'Oro, 156, 00158 Rome
 - Molecular Oncogenesis Laboratory (Dr. A. Sacchi),
 - Kind of employment Senior Researcher Collaborator
 - Main duties and responsibilities Studies of gain of function activity of mutant p53 proteins in human cancer cell lines in vitro and in vivo through approaches of small interference RNA (RNAi).
- Date (from – to) January 2000 - January 2003
 - Name and address of the employer McMaster University, Hamilton, Ontario, Canada L8S 4K1
 - Life Science Building, department of biology (Prof. Frank L. Graham)
 - Kind of employment Post-Doc fellow
 - Main duties and responsibilities Modification of adenovirus type 5 cellular tropism through insertion of exogenous ligands into the HI loop of structural fiber
- Date (from – to) September 1995 - December 1999
 - Name and address of the employer IRCCS – Regina Elena National Cancer Institute, via delle Messi D'Oro, 156, 00158 Rome
 - Molecular Oncogenesis Laboratory (Dr. S. Soddu),
 - Kind of employment Student in Specialty
 - Main duties and responsibilities Gene therapy: bone marrow purging from leukemia cells by transduction of wild-type (wt) p53 onco-suppressor gene with recombinant retroviral vectors
- Date (da – a) March 1993 - July 1995

• Name and address of the employer	IRCCS – Regina Elena National Cancer Institute, via delle Messi D'Oro, 156, 00158 Rome;
• Type of business or sector	Molecular Oncogenesis Laboratory (Dr. S. Soddu),
• Kind of employment	Student Training
• Main duties and responsibilities	Gene therapy: bone marrow purging from neuroblastoma cells through the employment of regulatory regions at the 5' of Chromogranin A gene

LIST OF PUBLICATIONS

1. Stramucci L, **Bossi G***. "Approaching the challenges of MKK3/p38delta MAPK targeting for therapeutic purpose in colorectal cancer". *J Exp Clin Cancer Res.* 2019;38(1):504. doi: 10.1186/s13046-019-1513-4. **IF. 5.646**
2. Stramucci L, Pranteda A, Stravato A, Amoreo MG, Diodoro M, Bartolazzi A, Milella M, **Bossi G***. "MKK3 sustains cell proliferation and survival through p38DELTA MAPK activation in colorectal cancer". *Cell Death Dis.* 2019;10(11):842. doi: 10.1038/s41419-019-2083-2. **IF. 5.959**
3. Marconi R, Serafini A, Giovanetti A, Bartoleschi C, Pardini MC, **Bossi G***, Strigari L. "Cytokine modulation in breast cancer patients undergoing radiotherapy: a revision of the most recent studies". *Int. J. Mol. Sci.* 2019;20(2):382; <https://doi.org/10.3390/ijms20020382>. **IF. 4.183**
4. Loria R, Giliberti C, Bedini A, Palomba R, Caracciolo G, Ceci P, Falvo E, Marconi R, Falcioni R, **Bossi G***, Strigari L*. Low-intensity ultrasounds improve nanoparticles-complexes delivery in cancer cells in vitro: new insights for more efficient therapeutic strategies sparing normal cells. *J Exp Clin Cancer Res.* 2019;38(1):1. doi: 10.1186/s13046-018-1018-6. **IF. 5.646**
5. Stramucci L, Pranteda A, **Bossi G***. "Insights of Crosstalk between p53 Protein and the MKK3/MKK6/p38 MAPK Signaling" Pathway in Cancer. *Cancers (Basel).* 2018;10(5). pii: E131. doi: 10.3390/cancers10050131. Review. **IF. 6.162**
6. Marconi R, Strolin S, **Bossi G***, Strigari L. "A meta-analysis of the abscopal effect in preclinical models: is the biologically effective dose a relevant physical trigger?" *PLoS One.* 2017;12(2):e0171559. **IF. 2.776**
7. **Bossi G***. "MKK3 as oncotarget". *Aging (Albany NY).* 2016;8(1):1-2. **IF. 5.515**
8. Garibaldi F, Falcone E, Trisciuglio D, Colombo T, Lisek K, Walerych D, Del Sal G, Paci P, **Bossi G***, Piaggio G, Gurtner A. "Mutant p53 inhibits miRNA biogenesis by interfering with microprocessor complex". *Oncogene.* 2016;35(29):3760-70. doi: 10.1038/onc.2016.51. **IF. 7.519**
9. **Bossi G***. "mutant p53 and siL-1Ra". *Aging (Albany NY).* 2015;7(10):742-3. **IF. 5.515**
10. Garufi A, Ubertini V, Baldari S, D'Orazi V, **Bossi G***, D'Orazi G. "The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells". *J Exp Clin Cancer Res* 2015;34:87. DOI 10.1186/s13046-015-0206-x. **IF. 4.357**
11. Valente D, **Bossi G**, Moncada A, Tornincasa M, Indelicato S, Piscuoglio S, Karamitopoulou ED, Bartolazzi A, Pierantoni GM, Fusco A, Soddu S, Rinaldo C. "HIPK2 deficiency causes chromosomal instability by cytokinesis failure and increases tumorigenicity". *Oncotarget.* 2015;6(12):10320-34. **IF. 5.008**
12. Desantis A, Bruno T, Catena V, De Nicola F, Goeman F, Iezzi S, Sorino C, Ponzoni M, **Bossi G**, Federico V, La Rosa F, Ricciardi MR, Lesma E, De Meo PD, Castrignanò T, Petrucci MT, Pisani F, Chesi M, Bergsagel PL, Floridi A, Tonon G, Passananti C, Blandino G, Fanciulli M. "Che-1-induced inhibition of mTOR pathway enables stress-induced autophagy". *EMBO J.* 2015;34(9):1214-30. doi: 10.15252/embj.201489920. **IF. 9.643**
13. Baldari S, Ubertini V, Garufi A, D'Orazi G, **Bossi G***. "Targeting MKK3 as a novel anticancer strategy: molecular mechanisms and therapeutical implications". *Cell Death Dis.* 2015;6:e1621. doi: 10.1038/cddis.2014.591. **IF. 5.378**
14. Ubertini V, Norelli G, D'Arcangelo D, Gurtner A, Cesareo E, Baldari S, Piaggio G, Nisticò P, Soddu S, Facchiano A, **Bossi G***. "Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted Interleukin-1 Receptor Antagonist". *Oncogene.* 2014;34(19):2493-504. doi: 10.1038/onc.2014.191. **IF. 8.459**
15. Garufi A, Pucci D, D'Orazi V, Cirone M, **Bossi G**, Avantageggiati ML, D'Orazi G. "Degradation of

- mutant p53H175 protein by Zn(II) through autophagy". *Cell Death Dis.* 2014;5:e1271; doi:10.1038/cddis.2014.217. **IF. 5.014**
16. Strigari L, Mancuso M, Ubertini V, Soriani A, Giardullo P, Benassi M, D'Alessio D, Leonardi S, Soddu S, **Bossi G**. "Abscopal effect of radiation therapy: interplay between radiation dose and p53 status". *Int J Radiat Biol.* 2014;90(3):248-55. **IF. 1.687**
 17. Falcone G, Mazzola A, Michelini F, **Bossi G**, Censi F, Biferi MG, Florida G, Federico M, Musio A, Crescenzi M. "Cytogenetic analysis of human cells reveals specific patterns of DNA damage in replicative and oncogene-induced senescence" *Aging Cell.* 2013;12(2):312-5. doi: 10.1111/ace1.12034. **IF. 5.939**
 18. Folgiero V, Di Carlo SE, Bon G, Spugnini EP, Di Benedetto A, Germoni S, Ciullo S, Gentileschi MP, Accardo A, Milella M, Morelli G, **Bossi G**, Mottolese M, Falcioni R. "Inhibition of p85, the non-catalytic subunit of phosphatidylinositol 3-kinase, exerts potent antitumor activity in human breast cancer cells". *Cell Death Dis.* 2012;3:e440. doi: 10.1038/cddis.2012.179. **IF. 6.044**
 19. Catalano S, Panza S, Malivindi R, Giordano C, Barone I, **Bossi G**, Lanzino M, Sirianni R, Mauro L, Sisci D, Bonofiglio D, Ando S. "Inhibition of leydig tumor growth by farnesoid X receptor activation: The in vitro and in vivo basis for a novel therapeutic strategy". *Int J Cancer.* 2013;132(10):2237-47. doi: 10.1002/ijc.27915. **IF. 5.007**
 20. MacLeod SH, Elgadi MM, **Bossi G**, Sankar U, Pisio A, Agopsowicz K, Sharon D, Graham FL and Hitt MM. HER3-targeting of adenovirus by fiber modification increases infection of breast cancer cells in vitro, but not following intratumoral injection in mice. *Cancer Gene Ther.* 2012;19(12):888-98. doi: 10.1038/cgt.2012.79. **IF. 2.945**
 21. Goeman F, Manni I, Artuso S, Ramachandran B, Toietta G, **Bossi G**, Rando G, Cencioni C, Germoni S, Straino S, Capogrossi MC, Bacchetti S, Maggi A, Sacchi A, Ciana P, Piaggio G. "Molecular imaging of NF- κ B transcriptional activity maps proliferation sites in live animals. *Mol Biol Cell.* 2012;23(8):1467-74. doi: 10.1091/mbc.E12-01-0039. **IF. 4.604**
 22. Madaro L, Pelle A, Nicoletti C, Crupi A, Marrocco V, **Bossi G**, Soddu S, Bouché M. "PKC Theta Ablation Improves Healing in a Mouse Model of Muscular Dystrophy". *PLoS One* 2012;7(2):e31515. doi: 10.1371/journal.pone.0031515. **IF. 3.730**
 23. Barone I, Catalano S, Gelsomino L, Marsico S, Giordano C, Panza S, Bonofiglio D, **Bossi G**, Covington KR, Fuqua S, Ando S. "Leptin mediates tumor-stromal interactions that promote the invasive growth of breast cancer cells." *Cancer Res.* 2012;72(6):1416-27. doi: 10.1158/0008-5472.CAN-11-2558. **IF. 8.650**
 24. Norelli G, **Bossi G***. "Zinc, a promising mineral for misfolded p53 reactivation". *Cell Cycle* 2011;10(15):2415-6. doi: 10.4161/cc.10.15.15930. **IF. 5.359**
 25. Catalano S, Mauro L, Bonofiglio D, Pellegrino M, Qi H, Rizza P, Vizza D, **Bossi G**, Andò S. "In Vivo and in Vitro Evidence That PPAR γ Ligands Are Antagonists of Leptin Signaling in Breast Cancer". *Am J Pathol.* 2011;179(2):1030-40. doi: 10.1016/j.ajpath.2011.04.026. **IF. 4.890**
 26. Bruno T, Desantis A, **Bossi G**, Di Agostino S, Sorino C, De Nicola F, Iezzi S, Franchitto A, Benassi B, Galanti S, La Rosa F, Floridi A, Bellacosa A, Passananti C, Blandino G, Fanciulli M. "Che-1 Promotes Tumor Cell Survival by Sustaining Mutant p53 Transcription and Inhibiting DNA Damage Response Activation". *Cancer Cell.* 2010;18(2):122-134. doi: 10.1016/j.ccr.2010.05.027. **IF. 26.925**
 27. Tanno B, Sesti F, Cesi V, **Bossi G**, Ferrari-Amorotti G, Bussolari R, Tirindelli D, Calabretta B, Raschella G. "Expression of slug is regulated by C-MYB and is required for invasion and bone marrow homing of cancer cells of different origin". *J Biol Chem.* 2010;285(38):29434-45. doi: 10.1074/jbc.M109.089045. **IF. 5.328**
 28. Gurtner A, Starace G, Norelli G, Piaggio G, Sacchi A, **Bossi G***. "Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function". *J Biol Chem.* 2010;285(19):14160-9. doi: 10.1074/jbc.M109.094813. **IF. 5.328**
 29. Marampon F, **Bossi G**, Ciccarelli C, Di Rocco A, Sacchi A, Pestell R, Zani B. "MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma" *Mol. Cancer Ther.* 2009;8(3):543-51. doi: 10.1158/1535-7163.MCT-08-0570. **IF. 4.953**
 30. Nardinocchi L, Puca R, Guidolin D, Belloni AS, **Bossi G**, Sacchi A, Onisto M, D'Orazi G. "Regulation of tumor angiogenesis by HIPK2-induced repression of hypoxia-inducible factor 1 α ". *Biochim*

- Biophys Acta,2009; 1793(2):368-77. doi: 10.1016/j.bbamcr.2008.10.013. **IF. 4.81**
31. Puca R, Nardinocchi L, **Bossi G**, Sacchi A, Rechavi G, Givol D, D'Orazi G. "Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc". Exp Cell Res. 2009; 315(1):67-75. doi: 10.1016/j.yexcr.2008.10.018. **IF. 3.589**
 32. Vitali R, Mancini C, Cesi V, Tanno B, Mancuso M, **Bossi G**, Zhang Y, Martinez RV, Calabretta B, Dominici V, Raschella G. "Slug (SNAI2) down-regulation by RNA interference facilitates apoptosis and inhibits invasive growth in neuroblastoma preclinical models". Clinical Cancer Research, 2008;14(14):4622-30. doi: 10.1158/1078-0432.CCR-07-5210. **IF. 7.55**
 33. **Bossi G***, Marampon F, Maor-Aloni R, Zani B, Rotter V, Oren M, Strano S, Blandino G, Sacchi A. "Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy". Cell Cycle, 2008;7(12):1870-9. doi: 10.4161/cc.7.12.6161. **IF. 4.12**
 34. Mauro L, Catalano S, **Bossi G**, Pellegrino M, Barone I, Morales S, Giordano C, Bartella V, Casaburi I, Andò S. "Evidences that leptin upregulates E-cadherin expression in breast cancer: effects on tumor growth and progression". Cancer Res. 2007;67(7):3412-21. doi: 10.1158/0008-5472.CAN-06-2890 **IF. 8.79**
 35. **Bossi G***, Sacchi A. "Restoration of wt p53 function in human cancer: relevance of tumor therapy" Head and Neck, 2007;29(3):272-84. Review. doi: 10.1002/hed.20529. **IF. 2.37**
 36. **Bossi G***, Soddu S, Sacchi A. "p53 protein activation: insights". Trends in Cancer Research, 2006;2:63-70. Review.
 37. Cecchinelli B, Porrello A, Lazzari C, Gradi A, **Bossi G**, D'Angelo M, Sacchi A, Soddu S. "Ser58 of mouse p53 is the homologue of human Ser46 and is phosphorylated by HIPK2 in apoptosis" Cell Death Differ,2006;13(11):1994-7. doi: 10.1038/sj.cdd.4401933. **IF. 7.463**
 38. G. Bon, V. Folgiero, **Bossi G**, Felicioni L, Marchetti A, Sacchi A, Falcioni R. "Loss of [beta]4 integrin subunit reduces the tumorigenicity of MCF7 mammary cells and causes apoptosis upon hormon deprivation" Clin Cancer Res, 2006;12(11 Pt 1):3280-7. doi: 10.1158/1078-0432.CCR-05-2223. **IF. 5.79**
 39. **Bossi G***, Lapi E, Strano S, Rinaldo C, Blandino G, Sacchi A. " Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression" Oncogene, 2006;25(2):304-309. doi: 10.1038/sj.onc.1209026. **IF. 6.582**
 40. **Bossi G**, Mazzaro G, Porrello A, Crescenzi M, Soddu S, Sacchi A. "Wild-type p53 gene transfer is not detrimental to normal cells in vivo: implications for tumor gene therapy" Oncogene, 2004;23(2):418-25. doi: 10.1038/sj.onc.1207042. **IF. 6.318**
 41. Cerone MA, Marchetti A, **Bossi G**, Blandino G, Sacchi A, Soddu S. "p53 is involved in the differentiation but not in the differentiation-associated apoptosis of myoblasts" Cell Death Differ. 2000;7(5): 506-8. doi: 10.1038/sj.cdd.4400676. **IF. 5.701**
 42. Cristofanelli B, Valentinis B, Soddu S, Rizzo M.G, Marchetti A, **Bossi G**, Morena A.R, Dews M, Baserga R, Sacchi A. "Cooperative transformation of 32D cells by the combined expression of IRS-1 and V-Ha-Ras" Oncogene, 2000;19(29):3245-55. DOI: 10.1038/sj.onc.1203664. **IF. 5.979**
 43. **Bossi G**, Scardigli R, Musiani P, Martinelli R, Gentileschi M.P, Soddu S, Sacchi A. "Development of a murine orthotopic model of leukaemia: evaluation of TP53 gene therapy efficacy" Cancer Gene Ther. 2000;7(1):135-43. doi:10.1038/sj.cgt.7700101. **IF. 2.945**
 44. G. Mazzaro, **G. Bossi**, S. Coen, A. Sacchi, and S. Soddu. "The role of wild-type p53 in the differentiation of primary hemopoietic and muscle cells" Oncogene 1999;18(42):5831-5. Doi:10.1038/sj.onc.1202962. **IF.5.979**
 45. R. Scardigli, **G. Bossi**, G. Blandino, M. Crescenzi, S. Soddu, and A. Sacchi. "Exogenous wt-p53 overexpression does not affect normal hematopoiesis: basis for bone marrow purging?" Gene Ther. 1997;4 (12): 1371-1378. doi:10.1038/sj.gt.3300530. **IF. 5.616**
 46. S. Soddu, G. Blandino, R. Scardigli, S. Coen, A. Marchetti, M.G. Rizzo, G. Bossi, L. Cimino, M. Crescenzi, and A. Sacchi "Interference with p53 protein inhibits hematopoietic and muscle differentiation". J. Cell Biol. 1996;134(1):193-204. doi:10.1083/jcb.134.1.193. **IF. 12.522**
 47. C. Gaetano, I. Manni, **G. Bossi**, G. Piaggio, S. Soddu, A. Farina, L. J. Helman, and A. Sacchi. "Retinoic acid and c-AMP differentially regulate human chromogranin A promoter activity during differentiation of neuroblastoma cells". Eur. J. Cancer 1995;31A(4): 447-452. doi:10.1016/0959-

*Corresponding, co-Last, Last Author

TOTAL IMPACT FACTOR: 277,855

H INDEX: 23

COMMUNICATIONS.

CONTRIBUTED TO MORE THAN N. 80 COMMUNICATIONS TO WORKSHOPS
OF WHICH N. 22 AS FIRST / LAST / SELECTED ORAL PRESENTATIONS

COLLABORATE AS REVIEWER WITH THE FOLLOWING JOURNALS:

Cancer Research; FEBS; Cell Death and Disease (CDDIS); BMC Veterinary Research; Comparative and Functional Genomics; International Journal of Genomics; Journal of Experimental & Clinical Cancer (JECCR); J. Oncology; International J of Nanomedicine; International J. of Genomics; MDPI Journals; DovePress.

MEMBER OF FOLLOWING SCIENTIFIC ASSOCIATIONS:

Membro Associazione di Biologia Cellulare e del Differenziamento, dal 2012.
Associazione Italiana di Colture Cellulari Onlus, dal 2014

**PERSONAL SKILLS AND
COMPETENCES**

*Acquired during life and career but
not necessarily recognized by
official certificates and diplomas.*

FIRST LANGUAGE	ITALIAN
OTHER LANGUAGES	ENGLISH
<ul style="list-style-type: none">• <i>Reading Ability</i>• <i>Writing Skills</i>• Oral Expression Skills	Excellent Excellent Excellent
RELATIONAL SKILLS AND COMPETENCES	Good interpersonal skills and competences at national and international level acquired through the experience of research work in various laboratories both in Italy and abroad.
ORGANIZATIONAL SKILLS.	Excellent organizational skills, coordination and management of both human and material resources acquired both through the management of research projects at manager level, and through the supervision and training of research work for students and doctoral students in biological disciplines.
TECHNICAL SKILLS	Cell Biology: Cell cultures of both stabilized and primary lines. Derivation, amplification and purification of primary, stem, tumor cells, terminally differentiated, obtained from various animal and human tissues or biopsies. Production, amplification, purification and titration of retro-adoeno-lentiviral constructs. Gene transduction for over-expression and silencing by

transfection or infection. Determination of cellular functions such as proliferation, migration, apoptosis, differentiation and neoplastic transformation. Retention and manipulation of primary hematopoietic murine cultures.

Molecular Biology: Extraction and purification of nucleic acids from cells and tissues, genetic engineering, cloning, mutagenesis, creation of expression constructs or gene silencing of both plasmid and viral type. Determination of gene expression by means of RNA analysis (Northern blots, RT-PCR and Real-Time PCR).

Biochemistry: Systems for the expression of recombinant proteins, main analysis techniques of protein expression such as Western-Blot, immunocytochemistry, immunofluorescence, immunohistochemistry. Elisa assays

In vivo studies: Experience in the handling of laboratory animals, generation and characterization of experimental models (xenograft, orthotopic) for the study of the efficiency of anti-tumor therapeutic treatments; experience in bone marrow transplantation in mouse models; experience in in vivo RNAi studies with constitutive and inducible expression models in mouse models, maintenance of mouse colonies, genotyping, in vivo imaging.

Good computer skills related to the use of Windows and MacOS operating systems.

The undersigned is aware that, pursuant to art. 26 of Law 15/68, false declarations, falsehood in the documents and the use of false documents are punished according to the penal code and special laws. Furthermore, the undersigned authorizes the processing of personal data, including sensitive data, pursuant to and for the purposes of Legislative Decree 196/2003 for the purposes referred to in this application notice.

Date 30/01/2020

Sign Gianluca Bossi

A handwritten signature in black ink, appearing to read 'Gianluca Bossi', written in a cursive style.